The Current Ratio as of November 2024 (TTM) for GT Biopharma, Inc. (GTBP) is 1.45

According to GT Biopharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.45. This represents a change of -29.13% compared to the average of 2.05 of the last 4 quarters.

GT Biopharma, Inc. (GTBP) Historical Current Ratio (quarterly & annually)

How has GTBP Current Ratio performed in the past?

The mean historical Current Ratio of GT Biopharma, Inc. over the last ten years is 0.90. The current 1.45 Current Ratio has changed 15.94% with respect to the historical average. Over the past ten years (40 quarters), GTBP's Current Ratio was at its highest in in the June 2021 quarter at 12.08. The Current Ratio was at its lowest in in the December 2015 quarter at 0.00.

GT Biopharma, Inc. (GTBP) Current Ratio by Quarter and Year

Discovering the peaks and valleys of GT Biopharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

GT Biopharma, Inc. (GTBP) Average Current Ratio

How has GTBP Current Ratio performed in the past?

The current Current Ratio of GT Biopharma, Inc. (GTBP) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

GT Biopharma, Inc. (GTBP) Current Ratio vs. Peers

How is GTBP’s Current Ratio compared to its peers?

GT Biopharma, Inc.’s Current Ratio is less than Allarity Therapeutics, Inc. (2.75), less than NeuroBo Pharmaceuticals, Inc. (2.41), less than Hillstream BioPharma, Inc. (2.25), less than Virax Biolabs Group Limited (25.94), less than Quoin Pharmaceuticals, Ltd. (3.02), greater than Panbela Therapeutics, Inc. (0.26), greater than Virpax Pharmaceuticals, Inc. (0.13), less than Revelation Biosciences, Inc. (1.64), less than Biodexa Pharmaceuticals Plc (2.16), less than Praxis Precision Medicines, Inc. (10.96), less than Pulmatrix, Inc. (19.40), less than Oncorus, Inc. (1.74), greater than Akari Therapeutics, Plc (0.29), less than Sonnet BioTherapeutics Holdings, Inc. (1.65), less than Landos Biopharma, Inc. (4.43), less than Cingulate Inc. (7.35K), less than SAB Biotherapeutics, Inc. (3.69), less than Anebulo Pharmaceuticals, Inc. (3.45), less than Cadrenal Therapeutics, Inc. Common Stock (3.69), less than Monopar Therapeutics Inc. (5.41K), less than Protara Therapeutics, Inc. (9.85), greater than Vaccinex, Inc. (0.77), less than Miromatrix Medical Inc. (3.46), less than Surrozen, Inc. (7.40),

Build a custom stock screener for GT Biopharma, Inc. (GTBP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GT Biopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

GT Biopharma, Inc. (GTBP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like GT Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.